Summary
This 8-K filing by Pfizer Inc. (PFE) on October 21, 2009, announces the official completion of its acquisition of Wyeth, a significant event for the pharmaceutical giant. The merger, effective as of October 15, 2009, involved a cash and stock transaction where Wyeth shareholders received $33.00 in cash and 0.985 shares of Pfizer common stock for each Wyeth share. This acquisition marks a strategic move to expand Pfizer's product portfolio and market presence. The filing also incorporates by reference key financial statements and pro forma combined financial information for both Pfizer and Wyeth. This includes audited financial statements for Wyeth for the years ended December 31, 2008 and 2007, as well as unaudited interim financial statements for Wyeth as of June 30, 2009. The pro forma statements provide a look at the potential combined financial performance. Investors should note the inclusion of forward-looking statements and associated risks, particularly regarding the realization of expected synergies and integration challenges.
Key Highlights
- 1Pfizer Inc. officially completed its acquisition of Wyeth on October 15, 2009.
- 2Wyeth shareholders received $33.00 in cash and 0.985 shares of Pfizer common stock per Wyeth share.
- 3The merger creates a combined entity with a potentially expanded product portfolio and market reach.
- 4The filing includes financial statements of Wyeth and pro forma combined financial statements for both companies.
- 5Risks associated with the merger, including synergy realization and integration challenges, are disclosed.
- 6The transaction was structured as a merger between Wyeth and Pfizer's subsidiary, Wagner Acquisition Corp.